Pharmacoinvasive Therapy With Prourokinase

The Efficacy and Safety of Pharmacoinvasive Therapy With Prourokinase for Acute ST Segment Elevation Myocardial Infarction Patients With Expected Percutaneous Coronary Intervention Related Delay

NCT01642667•Suzhou Landing Pharmaceuticals

View on ClinicalTrials.gov

Summary

The aim of this study is to elucidate the efficacy and safety of pharmacoinvasive therapy by using prourokinase (prouk), a unique fibrin-specific agent, in patients with ST-segment elevation myocardial infarction (STEMI)

Eligibility

Age

0 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•age 75 years or younger, symptom onset 6 h or less before randomization, intention to undertake primary PCI, ST-segment elevation of 2 mm or more in two anterior leads or of 1 mm or more in two inferior leads if they had ST-segment elevation, or new left bundle-branch block.

Exclusion Criteria

•expected arrival at the catheterization laboratory less than 1 h or more than 3 h after randomization, anticipated problems with vascular access, previous enrollment to other studies, and the usual contraindications to thrombolytic therapy.

Locations (1)

Shenyang Northern Hospital

Shenyang, Liaoning, China

Key Dates

Start Date

November 1, 2008

Primary Completion Date

November 1, 2009

Completion Date

December 1, 2010

Last Updated

July 27, 2012

Enrollment

197

ACTUAL participants

Conditions

ST-segment Elevation Myocardial Infarction (STEMI)

Interventions

Prourokinase

DRUG

Placebo

DRUG

The Effect of Morning vs Evening Aerobic Exercise Training on Cardiac Remodeling and Function Improvement in Patients After ST Elevation Myocardial Infarction

NCT06385834

ST-segment Elevation Myocardial Infarction (STEMI)

View study

UNKNOWNPHASE4

The Efficacy and Safety of Ketotifen in Primary PCI Patients With STEMI

NCT05511831

ST-segment Elevation Myocardial Infarction (STEMI)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 27, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions